	Long-term risk of incident psoriasis in patients with irritable bowel syndrome: a large-scale prospective cohort study. J Glob Health Qiu Y, Zhou Y, Liu S, Zhang Q, Zhang S, Wu J, Zhu S, Wu S. PMID: 42565434 [PubMed - indexed for MEDLINE]
	Clinical characteristics and outcomes of paradoxical palmoplantar pustulosis during secukinumab therapy in biologic-naÃ¯ve patients with plaque psoriasis: aÂ retrospective case series. J Dermatolog Treat Si Q, Zhang Y, Li J, Zhu N, Li Z, Yan H, Wu R, He X, Liu L, Mu Q. PMID: 42565330 [PubMed - indexed for MEDLINE]
	Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study. EClinicalMedicine Ali F, Wright AK, Graier T, El Sayed M, Giles RH, Lambert J, French LE, Lim HW, Ashcroft DM, C M van de Kerkhof P, Griffiths CEM, Gavan SP, Lwin SM. PMID: 42564855 [PubMed]
	Efficacy and safety of interleukin inhibitors in the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Front Med (Lausanne) Ming J, Jiang Y, Wu Q, Xiao X, Chen M. PMID: 42564794 [PubMed]
	Post-transcriptional regulation via alternative polyadenylation and piRNA shapes macrophage responses in psoriasis. Front Immunol Lin B, Du X, Lu L, Wang Z, Zhao Y, Feng Y, Liu L. PMID: 42564021 [PubMed - indexed for MEDLINE]
	Durability of response to Icotrokinra in the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials: a potential new novel oral treatment for psoriasis. Br J Dermatol Millette D. PMID: 42563545 [PubMed - as supplied by publisher]
	Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. Am J Clin Dermatol Armstrong AW, Lebwohl M, Warren RB, Morita A, Paul C, Thaçi D, Augustin M, Puig L, Daamen C, Li J, Alió A, Aggrey-Amable A, Scotto J, Popmihajlov Z, Vaile J, Strober B. PMID: 42563042 [PubMed - as supplied by publisher]
	Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial. Ann Rheum Dis van der Heijde D, Mease PJ, Paul C, Behrens F, Gossec L, Kaneko Y, Eder L, Coates LC, Pink AE, Wan W, Soriano ER, Leszczy, Scher JU, Deodhar A, Pachai C, Li J, Fan X, Rabbat S, Sardinas C, Vritzali E, Vaile J, Merola JF. PMID: 42562758 [PubMed - as supplied by publisher]
	Injection Site Pain Levels with Biologic Medications for Atopic Dermatitis and Psoriasis: A Real-Life Study. J Am Acad Dermatol Karpoff K, Lau WC, Lebwohl M. PMID: 42562102 [PubMed - as supplied by publisher]
	Clinical Characteristics, Management, and Outcomes of Dupilumab-Induced Psoriasis and Psoriasiform Eruptions: A Systematic Review. J Am Acad Dermatol Wen S, Adam Bai JQ, Rao V, Liu C. PMID: 42562093 [PubMed - as supplied by publisher]
	Melittin attenuates imiquimod-induced psoriatic dermatitis in mice: a role for autophagy activation via PI3K/Akt/mTOR pathway suppression. Saudi Pharm J Hafez SA, Ahmed AA, Elkhoely A, Ahmed AAE. PMID: 42560464 [PubMed]
	Drug-associated psoriasis: a pharmacovigilance study based on the FAERS database. Front Pharmacol Yi S, Liu A, Huoshen W, Xia D, Ma X. PMID: 42558881 [PubMed]
	Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. Front Immunol Zhang S, Lam T, Du Y, Chen X, Zhang H, Li L, Zhang G. PMID: 42558790 [PubMed - indexed for MEDLINE]
	Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials. J Dermatol Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki M. PMID: 42557591 [PubMed - as supplied by publisher]
	Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial. Naunyn Schmiedebergs Arch Pharmacol Wang S, Zhang Z, Han L, Yan K, Xu J. PMID: 42557368 [PubMed - as supplied by publisher]
	Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast. Dermatology Raimondo A, Balato A, Guarneri C, Ligrone L, Manzo R, Megna M, Musumeci ML, Palazzo G, Puca RV, Romano F, Lembo S. PMID: 42555537 [PubMed - as supplied by publisher]
	Efficacy of Heartfulness Meditation as Adjunctive Therapy for Moderate to Severe Psoriasis: A Randomised Controlled Trial. Indian J Dermatol Nagendran P, Subramanian SK, Satyanarayanan, Sripad VD, Rajendran R, Gopinath H, Sravanthi KL, Thiruveedhula H. PMID: 42555361 [PubMed]
	INDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management. J Drugs Dermatol Issa NT, Lebwohl M, Chovatiya R, Kircik L. PMID: 42555081 [PubMed - indexed for MEDLINE]
	Impact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol. J Drugs Dermatol Alqefari AN, Almutairi HM, Almohaimeed MY, Aldossari AA, Alqefari G, Alsaleam A, Alzolibani AA, Alhameedy M. PMID: 42555076 [PubMed - indexed for MEDLINE]
	Improved Sleep Quality in Psoriasis Patients Under Biologicals: A Prospective Observational Study. J Drugs Dermatol De Luca DA, Papara C, Pommerien L, Hawro T, Thaçi D. PMID: 42555075 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 28362

Page 1 of 1419



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy